Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.

BACKGROUND Antipsychotic drugs improve schizophrenia symptoms and reduce the frequency of relapse, but treatment response is highly variable. Little is known about the genetic factors associated with treatment response. We did a genome-wide association study of antipsychotic treatment response in patients with schizophrenia. METHODS The discovery cohort comprised patients with schizophrenia from 32 psychiatric hospitals in China that are part of the Chinese Antipsychotics Pharmacogenomics Consortium. Patients who met inclusion criteria were randomly assigned (1:1:1:1:1:1) to six groups (olanzapine, risperidone, quetiapine, aripiprazole, ziprasidone, and haloperidol or perphenazine; those assigned to haloperidol or perphenazine were subsequently assigned [1:1] to one or the other) for 6 weeks. Antipsychotic response was quantified with percentage change on the Positive and Negative Syndrome Scale. Single-nucleotide polymorphisms (SNPs) were tested for their association with treatment response. Linkage-disequilibrium-independent SNPs that exhibited potential associations (ie, p<1 × 10-5) were tested in a validation cohort comprising patients from the Chinese Antipsychotics Pharmacogenetics Consortium from five collaborative hospitals, who were treated with olanzapine, risperidone, or aripiprazole for 8 weeks. FINDINGS The discovery cohort contained 2413 patients and the validation cohort 1379 patients. In the discovery cohort, we identified three novel SNPs (rs72790443 in MEGF10 [p=1·37 × 10-8], rs1471786 in SLC1A1 [p=1·77 × 10-8], and rs9291547 in PCDH7 [p=4·48 × 10-8]) that were associated with antipsychotic treatment response at a genome-wide significance level. These associations were confirmed in the validation cohort (p<0·05). In the combined sample of the discovery and validation cohorts, we identified five novel loci showing genome-wide significant associations with general antipsychotic treatment response (rs72790443 in MEGF10 [p=1·40 × 10-9], rs1471786 in SLC1A1 [p=2·33 × 10-9], rs9291547 in PCDH7 [p=3·24 × 10-9], rs12711680 in CNTNAP5 [p=2·12 × 10-8], and rs6444970 in TNIK [p=4·85 × 10-8]). In antipsychotic-specific groups, after the combination of results from both samples, the rs2239063 SNP in CACNA1C was associated with treatment response to olanzapine (p=1·10 × 10-8), rs16921385 in SLC1A1 was associated with treatment response to risperidone (p=4·40 × 10-8), and rs17022006 in CNTN4 was associated with treatment response to aripiprazole (p=2·58 × 10-8). INTERPRETATION We have identified genes related to synaptic function, neurotransmitter receptors, and schizophrenia risk that are associated with response to antipsychotics. These findings improve understanding of the mechanisms underlying treatment responses, and the identified biomarkers could eventually guide choice of antipsychotic in patients with schizophrenia. FUNDING National Key Technology R&D Program of China, National Natural Science Foundation of China.

[1]  J A Badner,et al.  Chronic behavioral stress exaggerates motor deficit and neuroinflammation in the MPTP mouse model of Parkinson's disease , 2016, Translational Psychiatry.

[2]  D. Braus,et al.  Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain , 2003, Neuroscience Letters.

[3]  P. Sullivan,et al.  Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment , 2013, Pharmacogenetics and genomics.

[4]  M. Kanai,et al.  Empirical estimation of genome-wide significance thresholds based on the 1000 Genomes Project data set , 2016, Journal of Human Genetics.

[5]  J. Lieberman Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. , 2007, The Journal of clinical psychiatry.

[6]  H. Meltzer,et al.  Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes , 2017, Schizophrenia Research.

[7]  M. Polymeropoulos,et al.  Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study , 2009, Molecular Psychiatry.

[8]  Vladimir I. Vladimirov,et al.  Genomewide Pharmacogenomic Analysis of Response to Treatment with Antipsychotics , 2009, Molecular Psychiatry.

[9]  Manuel A. R. Ferreira,et al.  Practical aspects of imputation-driven meta-analysis of genome-wide association studies. , 2008, Human molecular genetics.

[10]  M. Lambert,et al.  Incomplete remission and treatment resistance in first-episode psychosis: definition, prevalence and predictors , 2008 .

[11]  P. Greengard,et al.  The alpha and gamma 1 isoforms of protein phosphatase 1 are highly and specifically concentrated in dendritic spines. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  H. Möller,et al.  Should the PANSS be rescaled? , 2010, Schizophrenia bulletin.

[13]  A. Minelli,et al.  The GRM7 gene, early response to risperidone, and schizophrenia: a genome-wide association study and a confirmatory pharmacogenetic analysis , 2016, The Pharmacogenomics Journal.

[14]  W. Gauderman Candidate gene association analysis for a quantitative trait, using parent‐offspring trios , 2003, Genetic epidemiology.

[15]  D. Reich,et al.  Principal components analysis corrects for stratification in genome-wide association studies , 2006, Nature Genetics.

[16]  D. Rujescu,et al.  Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment , 2014, Pharmacogenetics and genomics.

[17]  J. Lieberman,et al.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.

[18]  Jun S. Liu,et al.  The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans , 2015, Science.

[19]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[20]  P. Visscher,et al.  GCTA: a tool for genome-wide complex trait analysis. , 2011, American journal of human genetics.

[21]  Manuel A. R. Ferreira,et al.  PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.

[22]  Marcelo P. Coba,et al.  Knockdown of mental disorder susceptibility genes disrupts neuronal network physiology in vitro , 2011, Molecular and Cellular Neuroscience.

[23]  S. Kapur,et al.  Early Response to Antipsychotic Drug Therapy as a Clinical Marker of Subsequent Response in the Treatment of Schizophrenia , 2010, Neuropsychopharmacology.

[24]  H. Himmelbauer,et al.  New members of the neurexin superfamily: multiple rodent homologues of the human CASPR5 gene , 2006, Mammalian Genome.

[25]  Kei Ito,et al.  Essential Role of the Apoptotic Cell Engulfment Genes draper and ced-6 in Programmed Axon Pruning during Drosophila Metamorphosis , 2006, Neuron.

[26]  A. Malhotra,et al.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction , 2011, Expert opinion on drug metabolism & toxicology.

[27]  Shitij Kapur,et al.  Delayed-Onset Hypothesis of Antipsychotic Action: A Hypothesis Tested and Rejected , 2003 .

[28]  J. Moncrieff,et al.  Trends in prescriptions and costs of drugs for mental disorders in England, 1998-2010. , 2012, The British journal of psychiatry : the journal of mental science.

[29]  Hans Clevers,et al.  The kinase TNIK is an essential activator of Wnt target genes , 2009, The EMBO journal.

[30]  N. Schork,et al.  Genome-wide association study of paliperidone efficacy , 2016, Pharmacogenetics and genomics.

[31]  A. Singleton,et al.  Genetic variability in the regulation of gene expression in ten regions of the human brain , 2014, Nature Neuroscience.

[32]  G. Thaker,et al.  Advances in schizophrenia , 2001, Nature Medicine.

[33]  J. Kane,et al.  Early-Onset Hypothesis of Antipsychotic Drug Action: A Hypothesis Tested, Confirmed and Extended , 2005, Biological Psychiatry.

[34]  K. Yoshitomo-Nakagawa,et al.  Cloning, expression analysis, and chromosomal localization of BH-protocadherin (PCDH7), a novel member of the cadherin superfamily. , 1998, Genomics.

[35]  M. Arranz,et al.  Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research , 2007, Molecular Psychiatry.

[36]  A. Hayashi‐Takagi,et al.  The psychiatric disease risk factors DISC1 and TNIK interact to regulate synapse composition and function , 2011, Molecular Psychiatry.

[37]  Elior Peles,et al.  The local differentiation of myelinated axons at nodes of Ranvier , 2003, Nature Reviews Neuroscience.

[38]  O. Delaneau,et al.  Supplementary Information for ‘ Improved whole chromosome phasing for disease and population genetic studies ’ , 2012 .

[39]  R. Swanson,et al.  Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse , 2006, Nature Neuroscience.

[40]  P. Donnelly,et al.  A Flexible and Accurate Genotype Imputation Method for the Next Generation of Genome-Wide Association Studies , 2009, PLoS genetics.

[41]  Stephen J. Smith,et al.  Astrocytes mediate synapse elimination through MEGF10 and MERTK pathways , 2013, Nature.

[42]  E. Eskin,et al.  Integrating Functional Data to Prioritize Causal Variants in Statistical Fine-Mapping Studies , 2014, PLoS genetics.